Burst Wave Lithotripsy: Insights on Effectiveness and Safety

Early clinical data suggests BWL fragments kidney and ureteral stones in awake patients with mostly minor side effects — but the evidence base is still thin.

Journal: Current Opinion in Urology | Published: 2026-03-05 | Type: Narrative Review | PMID: 41823271 Authors: Katsimperis S, Tonyali S, Tzelves L (Second Dept. of Urology, National & Kapodistrian University of Athens; EAU Young Academic Urologists Working Group) Funding/COI: Not disclosed

Summary

Burst wave lithotripsy (BWL) uses short bursts of focused ultrasound — distinct from conventional shock wave lithotripsy (SWL) — to fragment urinary stones without general anesthesia. This narrative review synthesizes experimental, preclinical, and first-in-human data suggesting BWL can break stones of varied compositions while patients remain awake and tolerating the procedure. The authors position it as a complementary, not replacement, technology, and acknowledge that large prospective trials defining optimal patient selection are still pending.

Claims

• BWL can fragment stones across multiple compositions, with fragment size adjustable via frequency modulation
• Clinical studies report high stone comminution rates and "excellent tolerability" in awake patients — specific success-rate figures are not extracted in the abstract
• Adverse events described as predominantly low-grade
• Combining BWL with ultrasonic propulsion improved stone-free rates and fragment passage
• Preclinical data, including anticoagulated animal models, show a favorable renal safety profile

Study Quality

This is a narrative review — the weakest form of evidence synthesis. The authors did not conduct a systematic search, apply PRISMA methodology, or pool quantitative outcomes. The "first-in-human" framing is a tell: the clinical evidence underpinning this review is early-phase, small-sample, and almost certainly not randomized. Narrative reviews in surgical subspecialties are notoriously prone to selection bias, amplifying positive results while underweighting null or negative findings. No funding source or conflicts of interest are disclosed, which is a red flag for a technology that is presumably being commercialized.

Red Flags

• Narrative review format: author-selected studies, no systematic search, no pooled statistics
• "First-in-human" clinical base means sample sizes are almost certainly tiny
• No funding or COI disclosed — this is a problem for a review of a novel device
• No head-to-head comparison data against standard SWL or ureteroscopy with specific numbers
• "Promising complementary technology" framing is the authors' opinion, not a measured conclusion
• Abstract provides no actual stone-free rates, complication rates, or effect sizes — a review that reports no numbers is a flag

Strengths

• Timely synthesis of an emerging technology with genuine theoretical advantages over SWL (reduced tissue injury, no anesthesia requirement)
• Covers both preclinical and early clinical evidence, which is appropriate given where BWL sits in its development arc
• Authors note that ongoing trials will be needed — intellectually honest about the evidence gap

Verdict

This review tells you BWL exists, works in labs and small early trials, and hurts less than SWL. What it cannot tell you — because the data don't yet exist — is whether it works as well as ureteroscopy for complex stones, what the real complication profile looks like at scale, or which patients should get it. The missing COI disclosure is a problem for a device-adjacent review. Worth a read if you're tracking the technology, but don't mistake this for clinical-grade guidance on where BWL fits in practice.